MCID: PDT015
MIFTS: 31

Pediatric Supratentorial Ependymoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Pediatric Supratentorial Ependymoma

MalaCards integrated aliases for Pediatric Supratentorial Ependymoma:

Name: Pediatric Supratentorial Ependymoma 12 15
Childhood Supratentorial Ependymoma 12 17 72
Pediatric Supratentorial Ependymoblastoma 12
Pediatric Cerebral Ependymoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7502
NCIt 50 C9043
UMLS 72 C0278650

Summaries for Pediatric Supratentorial Ependymoma

MalaCards based summary : Pediatric Supratentorial Ependymoma, also known as childhood supratentorial ependymoma, is related to ependymoma and benign ependymoma, and has symptoms including seizures, vomiting and headache. An important gene associated with Pediatric Supratentorial Ependymoma is RELA (RELA Proto-Oncogene, NF-KB Subunit), and among its related pathways/superpathways are TNFR1 Pathway and Ras signaling pathway. The drugs Methotrexate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and bone.

Related Diseases for Pediatric Supratentorial Ependymoma

Diseases related to Pediatric Supratentorial Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 ependymoma 28.9 RELA EGFR C11orf95
2 benign ependymoma 10.4
3 anaplastic ependymoma 10.1
4 reticuloendotheliosis 9.4 RELA REL

Symptoms & Phenotypes for Pediatric Supratentorial Ependymoma

UMLS symptoms related to Pediatric Supratentorial Ependymoma:


seizures, vomiting, headache, nausea

Drugs & Therapeutics for Pediatric Supratentorial Ependymoma

Drugs for Pediatric Supratentorial Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
2
leucovorin Approved Phase 3 58-05-9 143 6006
3
Etoposide Approved Phase 3 33419-42-0 36462
4
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
11
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
12
Ondansetron Approved Phase 3 99614-02-5 4595
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
14 Folic Acid Antagonists Phase 3
15 Vitamin B9 Phase 3
16 Immunologic Factors Phase 3
17 Folate Phase 3
18 Nucleic Acid Synthesis Inhibitors Phase 3
19 Vitamin B Complex Phase 3
20 Immunosuppressive Agents Phase 3
21 Dermatologic Agents Phase 3
22 Antimetabolites, Antineoplastic Phase 3
23 Antimetabolites Phase 3
24 Antirheumatic Agents Phase 3
25 Antineoplastic Agents, Phytogenic Phase 3
26 Topoisomerase Inhibitors Phase 3
27 Etoposide phosphate Phase 3
28 Tubulin Modulators Phase 3
29 Alkylating Agents Phase 3
30 Antimitotic Agents Phase 3
31 Antineoplastic Agents, Alkylating Phase 3
32 Gastrointestinal Agents Phase 3
33 Antiemetics Phase 3
34 Peripheral Nervous System Agents Phase 3
35 Autonomic Agents Phase 3
36 Emetics Phase 3
37
Tamoxifen Approved Phase 2 10540-29-1 2733526
38
Sodium citrate Approved, Investigational Phase 2 68-04-2
39
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
40
Carmustine Approved, Investigational Phase 2 154-93-8 2578
41
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
42
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
43
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
44
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
45
Histamine Approved, Investigational Phase 2 51-45-6 774
46
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
47
Cyproheptadine Approved Phase 2 129-03-3 2913
48
Iodine Approved, Investigational Phase 2 7553-56-2 807
49
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
50
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
2 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
3 Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
4 Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
5 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
6 SIOP Study of Combined Modality Treatment in Childhood Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
7 PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS Completed NCT00002752 Phase 1, Phase 2
8 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
9 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
10 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
11 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
12 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
13 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
14 Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
15 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
16 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
17 Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
18 A Phase I/II Study Of A Recombinant Chimeric Protein Composed Of Transforming Growth Factor (TGF)-a And A Mutated Pseudomonas Exotoxin Termed PE38 (TP-38) In Pediatric Patients With Recurrent Or Progressive Supratentorial High Grade Gliomas Terminated NCT00074334 Phase 1, Phase 2
19 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue Withdrawn NCT00003273 Phase 2 carboplatin;cisplatin;cyclophosphamide;etoposide;leucovorin calcium;methotrexate;temozolomide;thiotepa;vincristine sulfate
20 Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
21 Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study Unknown status NCT00002647 Phase 1 verteporfin
22 PROTOCOL FOR A PHASE I STUDY OF INTRACYSTIC ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 IN THE TREATMENT OF PATIENTS WITH RECURRENT CYSTIC GLIOMAS Completed NCT00002753 Phase 1
23 A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00049023 Phase 1
24 Phase I Study of Intrathecal 131-I-3F8 Monoclonal Antibody in Patients With GD2 Positive Leptomeningeal Neoplasms Completed NCT00003022 Phase 1
25 A Phase I Trial and Pharmacokinetic Study of Talabostat (PT-100, Val-Boro-Pro) in Combination With Temozolomide or Carboplatin in Pediatric Patients With Relapsed or Refractory Solid Tumors Including Brain Tumors Completed NCT00303940 Phase 1 carboplatin;talabostat mesylate;temozolomide
26 Phase I Trial and Pharmacokinetic Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, on a 7 Day and 21 Day Dosing Schedule in Pediatric Patients With Refractory Solid Tumors Completed NCT00036959 Phase 1 ABT-751
27 A Phase I Study of Valproic Acid in Children With Recurrent/Progressive Solid Tumors Including CNS Tumors Completed NCT00107458 Phase 1 valproic acid
28 A Phase I Dose Escalation Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Pediatric Patients With Advanced Solid Tumors and Lymphomas Completed NCT00004212 Phase 1 exatecan mesylate
29 A Pilot Study of Intensive Chemotherapy With Peripheral Stem Cell Support for Infants With Malignant Brain Tumors Completed NCT00003141 Phase 1 carboplatin;cisplatin;cyclophosphamide;etoposide;thiotepa;vincristine sulfate
30 A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors Completed NCT00138216 Phase 1 irinotecan hydrochloride;temozolomide;vincristine sulfate
31 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents With Refractory Primary CNS Tumors Completed NCT00503724 Phase 1 enzastaurin hydrochloride
32 A Phase I Study of MK-0752 in Pediatric Patients With Recurrent or Refractory CNS Malignancies Terminated NCT00572182 Phase 1 MK-0752
33 Phase I Dose Escalation Study of N-Acetylcysteine Administered in Conjunction With Carboplatin, Cyclophosphamide, and Etoposide Phosphate BBBD, in Children With Malignant Brain Tumors Terminated NCT00238173 Phase 1 acetylcysteine;carboplatin;cyclophosphamide;etoposide phosphate;mannitol;sodium thiosulfate
34 A Phase I Pharmacokinetic Optimal Dosing Study of Intraventricular Topotecan for Children With Neoplastic Meningitis Terminated NCT00112619 Phase 1 topotecan hydrochloride
35 Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors Terminated NCT00623077 Phase 1 busulfan;etoposide;ifosfamide;melphalan;thiotepa;Mesna
36 A Phase I Study Of Talotrexin (PT-523) In Children And Adolescents With Recurrent Solid Tumors Or Recurrent/Refractory Leukemias Withdrawn NCT00458744 Phase 1 talotrexin
37 Analyses of Mutations Associated With Secondary Leukemia or Non-Hodgkin's Lymphoma in Patients Treated for Hodgkin's Disease or Childhood Brain Tumors Completed NCT00006342
38 Multicenter Therapy Optimizing Study for Treatment of Children and Adolescents With Intracranial Medulloblastoma / PNET and Ependymoma Completed NCT00303810 carboplatin;cisplatin;cyclophosphamide;etoposide phosphate;high-dose chemotherapy;lomustine;methotrexate;thiotepa;vincristine sulfate
39 Barriers to Patient Enrollment Onto Frontline Therapeutic Clinical Trials and Development of Intervention Strategies to Increase the Proportion of Enrollment Completed NCT00002485
40 Molecular and Histopathologic Characterization of Atypical Teratoid Rhabdoid Tumors, Choroid Plexus Carcinomas, Ependymomas, Medulloblastoma/PNET and Gliomas of the Pediatric CNS Recruiting NCT00897286
41 CCLG Observational Study of the Outcome of Ependymoma in Infants Diagnosed Before Their Third Birthday Active, not recruiting NCT00683319 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
42 Evaluation of Cerebral Spinal Fluid (CSF) Proteome and Angiogenesis Proteins in Children With Newly Diagnosed Central Nervous System Tumors Withdrawn NCT00897858

Search NIH Clinical Center for Pediatric Supratentorial Ependymoma

Genetic Tests for Pediatric Supratentorial Ependymoma

Anatomical Context for Pediatric Supratentorial Ependymoma

MalaCards organs/tissues related to Pediatric Supratentorial Ependymoma:

41
Brain, Liver, Bone

Publications for Pediatric Supratentorial Ependymoma

Articles related to Pediatric Supratentorial Ependymoma:

# Title Authors PMID Year
1
Pediatric Supratentorial Ependymoma: Surgical, Clinical, and Molecular Analysis. 38
29917116 2019
2
MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma. 38
30027327 2018
3
Long-term survival following gross total resection of pediatric supratentorial ependymomas without adjuvant therapy. 38
23948802 2012

Variations for Pediatric Supratentorial Ependymoma

Expression for Pediatric Supratentorial Ependymoma

Search GEO for disease gene expression data for Pediatric Supratentorial Ependymoma.

Pathways for Pediatric Supratentorial Ependymoma

Pathways related to Pediatric Supratentorial Ependymoma according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.61 RELA REL EGFR
2
Show member pathways
12.35 RELA REL EGFR
3
Show member pathways
12.33 RELA REL EGFR
4
Show member pathways
12.27 RELA REL EGFR
5
Show member pathways
12.23 RELA REL EGFR
6
Show member pathways
12.03 RELA REL EGFR
7
Show member pathways
11.97 RELA REL
8 11.96 RELA REL
9
Show member pathways
11.92 RELA REL
10
Show member pathways
11.91 RELA REL
11
Show member pathways
11.9 RELA REL
12
Show member pathways
11.89 RELA REL
13 11.76 RELA REL
14
Show member pathways
11.75 RELA REL
15
Show member pathways
11.75 RELA EGFR
16
Show member pathways
11.7 RELA REL
17
Show member pathways
11.69 RELA REL
18 11.68 RELA EGFR
19 11.62 RELA REL
20
Show member pathways
11.6 RELA REL
21
Show member pathways
11.59 RELA REL
22 11.58 RELA EGFR
23
Show member pathways
11.58 RELA REL EGFR
24
Show member pathways
11.47 RELA REL
25 11.46 RELA REL
26 11.42 RELA EGFR
27 11.41 RELA REL
28 11.4 RELA EGFR
29
Show member pathways
11.38 RELA REL
30 11.32 RELA REL
31 11.3 RELA REL
32
Show member pathways
11.3 RELA REL EGFR
33 11.29 RELA REL
34
Show member pathways
11.29 RELA REL
35
Show member pathways
11.25 RELA REL
36 11.22 RELA EGFR
37 11.12 RELA REL
38 11.1 RELA REL
39 11.02 RELA REL
40
Show member pathways
10.94 RELA REL
41 10.89 RELA REL
42
Show member pathways
10.49 RELA REL EGFR
43 10.4 RELA REL

GO Terms for Pediatric Supratentorial Ependymoma

Biological processes related to Pediatric Supratentorial Ependymoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.69 RELA REL EGFR
2 positive regulation of transcription, DNA-templated GO:0045893 9.61 RELA REL EGFR
3 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.49 RELA REL
4 response to organic cyclic compound GO:0014070 9.48 RELA EGFR
5 liver development GO:0001889 9.46 RELA EGFR
6 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.4 RELA REL
7 response to cytokine GO:0034097 9.37 RELA REL
8 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.32 RELA EGFR
9 hair follicle development GO:0001942 9.26 RELA EGFR
10 negative regulation of protein catabolic process GO:0042177 9.16 RELA EGFR
11 NIK/NF-kappaB signaling GO:0038061 8.96 RELA REL
12 response to cobalamin GO:0033590 8.62 RELA EGFR

Molecular functions related to Pediatric Supratentorial Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000980 8.96 RELA REL
2 chromatin binding GO:0003682 8.8 RELA REL EGFR

Sources for Pediatric Supratentorial Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....